A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2 Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 25 Sep 2019
Price : $35 *
At a glance
- Drugs Veliparib (Primary) ; Carboplatin; Paclitaxel
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie; AbbVie Germany
- 11 Feb 2019 Planned End Date changed from 30 May 2019 to 28 Apr 2020.
- 11 Feb 2019 Planned primary completion date changed from 30 May 2019 to 28 Apr 2020.
- 11 May 2018 Planned primary completion date changed from 31 May 2018 to 30 May 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History